Pharmacological Management of Fibromyalgia

Introduction to Fibromyalgia

Fibromyalgia is a condition characterized by chronic widespread musculoskeletal pain, fatigue, unrefreshing sleep, and cognitive issues, significantly impacting quality of life and healthcare utilization, with an average cost of over $2000 per patient per year 1

The American College of Rheumatology (ACR) criteria for diagnosing fibromyalgia include:

Criteria	Description
WPI	Widespread pain index
SS	Symptom severity scale
Tender point examination	Pain upon digital pressure in at least 11 of the 18 tender points, and a pressure of approximately 4 kg

The American College of Rheumatology and other guideline societies strongly recommend starting with non-pharmacological therapies for fibromyalgia, with exercise therapy having the strongest evidence base, which can improve global well-being and physical function in fibromyalgia patients 3, 4
Recommended non-pharmacological therapies for fibromyalgia include:
The American Journal of Transplantation recommends starting with low-intensity aerobic exercise and gradually increasing intensity as tolerated, while avoiding exercises that strain abdominal muscles within the first 6 months post-transplant 7
The European Heart Journal suggests individual or group counseling on coping with illness as part of psychological support 8
The American Journal of Transplantation and The Gut journal advise independent pre- and post-transplant emotional counseling and transplant support groups to address emotional adjustment 7, 9

First-line pharmacological treatment options for fibromyalgia include:
Second-line pharmacological treatment options for fibromyalgia include:
The American College of Rheumatology recommends the following medications for pain management:
NSAIDs and strong opioids are not recommended due to lack of efficacy and potential for harm, and corticosteroids are also not recommended due to lack of efficacy and potential for harm 5, 1

Pregnant patients with fibromyalgia should focus on non-pharmacological approaches to management 1, 5
Elderly patients with fibromyalgia should use lower initial doses of medications with gradual titration 1, 5
Patients with comorbid inflammatory arthritis should continue disease-modifying treatments while addressing fibromyalgia symptoms separately 1, 5
Patients with comorbid conditions should have their fibromyalgia symptoms addressed separately while continuing treatment for other conditions 1, 5
Cannabis should only be considered when conventional treatments have failed, the patient is informed about the limited evidence, and adequate follow-up for adverse effects can be ensured, according to the CDC and other health organizations 4

Regular monitoring and follow-up are necessary to assess the effectiveness of treatment and adjust the treatment plan as needed, as recommended by the American College of Rheumatology and other guideline societies 1, 5
Follow-up appointments should assess adherence to exercise program, symptom improvement, and need for additional interventions 1, 5
Regular follow-up appointments (every 2-4 weeks initially) are necessary to monitor treatment response, medication side effects, transplant medication adherence, liver function tests, sleep quality, and fatigue levels, although no specific citation is provided for this statement, it is implied by the context of the article and the importance of monitoring in the American Journal of Transplantation 7